Colistin as a salvage therapy for nosocomial infections caused by multidrug-resistant bacteria in the ICU.
The objective of this study was to determine the efficacy of systemic colistin therapy in the treatment of nosocomial infections caused by multidrug-resistant Acinetobacter baumannii or Pseudomonas aeruginosa and to study related adverse events. We prospectively studied 78 infections caused by multidrug-resistant A. baumannii or P. aeruginosa that were treated with colistin. The sites of infection were pulmonary infection (78.2%), urinary tract infection (7.7%), primary bloodstream infection (11.5%) and meningitis (2.6%). The mean daily dose of colistin was 5.5+/-1.1 MU/day (range 2-9 MU/day) and the mean duration of colistin therapy was 9.3+/-3.8 days (range 5-21 days). A favourable clinical response to colistin occurred in 60 cases (76.9%). Renal failure occurred in only seven cases. We conclude that colistin can be a safe and effective salvage therapeutic option for nosocomial infections caused by multidrug-resistant A. baumannii or P. aeruginosa.
Kallel
Hatem
H
Service de Réanimation Médicale, CHU Habib Bourguiba, route el Ain Km 1, 3029 Sfax, Tunisia. Kallelhat@yahoo.fr
Bahloul
Mabrouk
M
Hergafi
Leila
L
Akrout
Malek
M
Ketata
Wajdi
W
Chelly
Hedi
H
Hamida
Chokri Ben
CB
Rekik
Noureddine
N
Hammami
Adnane
A
Bouaziz
Mounir
M
D000151:Acinetobacter Infections / Q000188:drug therapy*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003091:Colistin / Q000008:administration & dosage / Q000627:therapeutic use*; D003428:Cross Infection / Q000188:drug therapy; D024901:Drug Resistance, Multiple, Bacterial; D006801:Humans; D007362:Intensive Care Units; D011446:Prospective Studies; D011552:Pseudomonas Infections / Q000188:drug therapy*; D016879:Salvage Therapy; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D003091:Colistin